Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC‐MPS) co‐administered with cyclosporine in the early‐phase post‐kidney transplantation

@article{Stracke2012PharmacokineticsAP,
  title={Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC‐MPS) co‐administered with cyclosporine in the early‐phase post‐kidney transplantation},
  author={Sylvia Stracke and Maria Shipkova and Jens M. Mayer and Frieder Keller and Amir Zarghom and Liying Yang and Doris Henne-Bruns and Eberhard Wieland},
  journal={Clinical Transplantation},
  year={2012},
  volume={26}
}
Stracke S, Shipkova M, Mayer J, Keller F, Zarghom A, Yang L, Henne‐Bruns D, Wieland E. Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC‐MPS) co‐administered with cyclosporine in the early‐phase post‐kidney transplantation. 
Clin Transplant 2012: 26: 57–66. 
© 2011 John Wiley & Sons A/S. 
Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation
TLDR
In patients treated with EC-MPS and Tac, monitoring MPA C0 may be important, as too high MPAC0 may contribute to anemia onset, and most of the MPA, fMPA and all MPAG concentrations correlated significantly with respective AUC0–12 values.
Efficacy and safety of enteric‐coated mycophenolate sodium in patients with de novo and maintenance renal transplantation
  • Y. Qin, F. Zhang, Y. Fan
  • Medicine, Biology
    International journal of clinical practice. Supplement
  • 2014
To evaluate the efficacy and safety of enteric‐coated mycophenolate sodium (EC‐MPS) in renal transplant patients treated de novo and for maintenance.
Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Exposure in Chinese Renal Allograft Recipients After Administration of EC‐MPS
TLDR
The PPK model was acceptable and can describe the pharmacokinetics of MPA in Chinese renal transplant recipients administered EC‐MPS and could be estimated through a limited sampling strategy method, based on which individualized immunosuppressive regimens could be designed.
Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus
TLDR
The pharmacokinetic profile of total and free MPA and its main metabolite MPAG was examined in Chinese adult renal transplant patients receiving EC-MPS and the use of LSS to estimate individual free and total MPA exposure could be useful in optimizing patient care.
Outcomes of EC-MPS combined with low-dose tacrolimus in DCD kidney transplantation for high-risk DGF recipients
TLDR
The immunosuppressive regime is applicable to Chinese kidney transplant recipients, and early low exposure to EC-MPS was related to acute rejection in the recipients at a high risk of DGF.
Early Immunosuppressive Exposure of Enteric-Coated-Mycophenolate Sodium Plus Tacrolimus Associated with Acute Rejection in Expanded Criteria Donor Kidney Transplantation
TLDR
Low-level exposure of MPA and Tac C0 in the early weeks posttransplant reflects an increased acute rejection risk, which suggested that MPA-AUC0-12h <30 mg·h-1·L-1 and TacC0 <4 ng/ml should be avoided in the first few weeks after transplantation.
Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update
TLDR
Mycophenolate is now the antimetabolite of choice in immunosuppressant regimens in transplant recipients, and the role of therapeutic drug monitoring (TDM) is still controversial and the ability of routine MPA TDM to improve long-term graft survival and patient outcomes is largely unknown.
The influence of UGT polymorphisms as biomarkers in solid organ transplantation.
Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients.
  • K. Yoshimura, I. Yano, K. Matsubara
  • Medicine, Biology
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2018
Therapeutic Drug Monitoring of Mycophenolic Acid.
...
...

References

SHOWING 1-10 OF 41 REFERENCES
The pharmacokinetic‐pharmacodynamic relationship for mycophenolate mofetil in renal transplantation
Pharmacokinetic and Pharmacodynamic Comparison of Enteric‐Coated Mycophenolate Sodium and Mycophenolate Mofetil in Maintenance Renal Transplant Patients
  • K. Budde, S. Bauer, P. Glander
  • Medicine, Biology
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2007
TLDR
Overall, IMPDH activity reflected MPA pharmacokinetics, and equimolar doses of EC‐MPS and MMF produce equivalent MPA exposure, while the delayed release formulation of EC-MPS exhibits more variable predose levels and Tmax.
Pharmacokinetics and variability of mycophenolic acid from enteric‐coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients
TLDR
Results indicate that a dose of EC‐MPS 1080 mg bid in combination with cyclosporine provides adequate systemic MPA exposure in de novo heart transplant patients, comparable with MMF 1500‰mg bid.
Enteric‐Coated Mycophenolate Sodium is Therapeutically Equivalent to Mycophenolate Mofetil in de novo Renal Transplant Patients
  • M. Salvadori, H. Holzer, M. Hall
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2004
TLDR
Therapeutic equivalence of EC‐MPS and MMF (1000 mg MMF b.i.d.), with concomitant cyclosporine microemulsion (Neoral®) and corticosteroids, was assessed in 423 de novo kidney transplant patients recruited to a 12‐month, double‐blind study.
Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients
TLDR
Therapeutic MMF drug monitoring might contribute to a better management of kidney transplant recipient with the goal of optimizing drug dosing and limiting the risk of MMF‐related toxicity.
The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy.
TLDR
Investigation of the pharmacokinetic (PK)/pharmacodynamic relationship of total and free MPA and PK values for the assessment of an individual's MPA PK parameters indicates that therapeutic drug monitoring of MPA has the potential for optimization of MMF efficacy in this patient population by steering patients away from the low values of M PA PK variables that are associated with an increased rejection risk.
Bioequivalence of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil: A Meta-Analysis of Three Studies in Stable Renal Transplant Recipients
TLDR
Findings provide reassurance to transplant professionals and patients that, when choosing between EC-MPS and MMF, they are choosing between formulations that give equivalent mycophenolate exposure.
Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation
  • Y. Le Meur, M. Büchler, P. Marquet
  • Medicine
    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • 2007
TLDR
Therapeutic MPA monitoring using a limited sampling strategy can reduce the risk of treatment failure and acute rejection in renal allograft recipients 12 months posttransplant with no increase in adverse events.
Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation
TLDR
A roundtable meeting to discuss the use of therapeutic drug monitoring (TDM) to guide immunosuppression with mycophenolate mofetil was held in New York in December 2004, and it was agreed that TDM might help optimize outcomes, especially in patients at higher risk of rejection.
...
...